LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
doi: 10.1016/j.pcad.2023.02.005
Melanie Speed, APRN, NP-C , takes pride in providing our clients with the latest innovations in wellness, including advanced weight management solutions like GLP-1 therapies
The product is among hundreds of dietary supplements and packaged foods trading off the nations burgeoning appetite for GLP-1 drugs, a powerful class of medications that can help with weight loss and blood sugar management
Here's a realistic clinical picture: semaglutide and tirzepatide have substantial clinical evidence as prescription weight-management tools for eligible patients when prescribed and monitored by qualified healthcare professionals
doi:10.1038/s41390-025-04228-1